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Systemic lupus erythematosus (SLE) is an autoimmune  disease characterized 
by excessive B lymphocyte proliferation (1) and the spontaneous production of 
autoantibodies reactive with a variety of self antigens (1). Studies (2, 3) involving 
the families of patients with SLE have shown that genetic factors play a role in 
the  development  of this  disorder.  We  have  recently  (4,  5)  reported  that  a 
characteristic of lupus-like diseases in mice is the abnormal expression of specific 
cellular oncogenes (protooncogenes). Our group has shown (5) that  B lympho- 
cytes from NZB and BXSB mice express increased quantities of the c-myc and N- 
ras protooncogenes.  In  light of the abnormalities  in protooncogene expression 
in  autoimmune  mice  and  the  excessive activation  of iymphocytes present  in 
humans  with  systemic autoimmune  diseases (6,  7),  we investigated cellular  on- 
cogene expression in such patients. 
Cellular oncogenes are DNA sequences homologous to the dominant growth- 
transforming  elements of certain  RNA tumor viruses (8).  In normal  cells they 
appear to be involved in the regulation of growth, activation, and differentiation 
(9-11).  The proteins encoded by one group of protooncogenes (myc, myb,  and 
fos)  are  found  in  the  nucleus,  and  are  believed to  modulate  gene  expression, 
whereas those encoded by other cellular oncogenes (e.g. the ras family) reside at 
the cell surface, where they apparently function in the generation or transduction 
of growth factor signals (8,  12-15). 
In  this  study  we report  that  the  expression  of selected  protooncogenes  by 
PBMC  of patients  with  SLE  differs significantly  from  that  of PBMC derived 
from normal  donors.  These differences were assessed by analyzing protoonco- 
gene expression by cells from patients  with nonlupus autoimmune diseases and 
by mitogen activated normal lymphocytes. 
Materials and Methods 
Source  and Preparation  of Cells.  All  patients  were  under  treatment  at  the  Clinical 
Center of the National  Institutes  of Health, Bethesda,  MD (Arthritis  and Rheumatism 
Branch). The technique of apheresis  was used to obtain 3-5 x  109 PBMC from patients 
and normal volunteers after written informed consent. All lupus patients met ARA criteria 
for SLE (16). Four of these patients  had very active disease as defined by major clinical 
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TABLE  I 
Clinical and Laboratory Evaluation of Patients with SLE 
Patient  Disease 
activity  Clinical symptoms 
Laboratory evaluation* 
Anti-  C  ESR  WBC  DNA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Very active 
Very active 
Very active 
Very active 
Active 
Active 
Active 
Active 
Active 
Active 
Active 
Active 
Inacttve 
Inactive 
Inactive 
Inactive 
Inactive 
Rash, psychiatric, myalgias, arthralgias  ~  T  0 
pleuritis, active glomerulonephritis  0  0  ~' 
Pericarditis,  active glomerulonephritis  ~  ~'  ~ 
Rash, psychiatric, arthralgias  0  ND  ~'  J, 
Active glomerulonephritis  0  0  1'  0 
Rash and fevers  0  ~'  ND 
Myalgias and arthritis  J,  1'  1' 
Rash, pleuritis  J,  ]'  ]' 
Pleuritis and abdominal inflammation  ~  ~  0 
Myalgias and arthralgias  0  ~  ~'  ~, 
Arthralgias,  pleuritis  ~  0  $  ~, 
Mild glomerulonephritis  0  )'  ]' 
Mild rash  0  0  0 
None  1  ~  ~' 
None  0  0  1"  0 
None  0  0  0 
None  ~  1'  0  0 
Laboratory evaluation  was done at the same  time that blood samples  were  obtained for RNA 
analysis. Several patients did not have all of the laboratory studies performed at this time. 
* C, hemolytic complement; anti-DNA, antibodies reactive with native DNA as measured by the Farr 
assay; ESR, erythrocyte sedimentation  rate measured by the Westergren method and corrected for 
sex and hematocrit; WBC, peripheral leukocyte count; ~, elevated  compared with age- and sex- 
matched normals with p <0.05, except for anti-DNA,  where p <0.01; $, reduced compared with 
age- and sex-matched  normals, p <0.05; 0, normal range; ND, not determined. 
involvement of at least two organ systems in association with expected laboratory abnor- 
malities. Eight had mild to moderately active disease affecting only one organ system, and 
the remaining five patients were in remission. The clinical and laboratory profiles of these 
patients  are  shown  in  Table  I.  Patients  with  other  autoimmune  processes,  including 
rheumatoid  arthritis,  Sjogren's  syndrome,  and  angioimmunoblastic  lymphadenopathy 
(AILD), had very active disease. 
Mononuclear cells were separated from other peripheral blood cells by density centrif- 
ugation  (17)  over  Lymphocyte  Separation  Medium  (Bionetics  Laboratory  Products, 
Charleston,  SC).  In  some  cases,  T  cells  were  isolated  by rosetting  PBMC  with  sheep 
erythrocytes, followed by density centrifugation (17). The resulting population contained 
94%  T  cells  and  <1%  B  cells  when  analyzed  on  a  FACS  (440;  Becton  Dickinson 
Immunocytometry Systems, Mountain View, CA) using fluorescein-labeled OKT 3 (anti- 
T  cell) and  anti-Ig reagents  as previously described  (17).  Macrophages were  removed 
from the T  cell-depleted pool by plastic adherence to yield a population containing 92% 
B cells and <2% T  cells by FACS analysis. 
Preliminary  experiments  were  conducted  to  determine  the  optimal  conditions  for 
studying protooncogene expression  in mitogen-activated human lymphocytes. Cell acti- 
vation was defined as an increase in RNA and/or DNA synthesis. This was measured by 
staining  lymphocytes with  acridine  orange and  then  analyzing their  fluorescence on a 
FACS 440 (Becton Dickinson Immunocytometry Systems) (18).  47%  of the T  cells and 
36%  of the  B  cells  were  activated  under  the  conditions  used  in  these  experiments, 
consisting of 5  #g/ml  Con A  for T  cells and  25  ug/ml  LPS for B cells.  All cells were 
cultured  in  RPMI  supplemented  with  a  mitogenic  FCS  (10%)  at  37°C  for  5  h  in  a 
humidified 5% CO2 in air incubator. 
Purification ofmRNA.  Pelleted lymphocytes were ruptured under ribonuclease-inacti- 
vating conditions by the method of Chirgwin et al.  (19).  RNA was separated from other 1294  DIFFERENTIAL ONCOGENE  EXPRESSION 
cellular constituents by centrifugation through a  cesium chloride gradient,  followed by 
repeated phenol/chloroform extractions (20). Poly(A)  ÷ RNA was obtained by passing total 
RNA over an oligo(dT)-cellulose column and eluting with low-sah buffer (21). 
Northern Blot Analysis of Protooncogene Expression.  10 #g of poly(A)  + RNA per subject 
were denatured in 14 mM methylmercury hydroxide, and then electrophoresed on 1.2% 
agarose gels containing 5 mM methylmercury hydroxide. The RNA was blotted onto 0- 
diazophenyl thioether  paper,  prehybridized,  and  then  hybridized  overnight  to a  nick- 
translated oncogene probe of sp act  1.4-2.0  ×  10  s cpm/tzg in 50%  formamide at 42°C 
(22). After washing at 65 °C in 0.1% SSC for 15-60 min, the blots were exposed to Kodak 
AR-2 film at -70 °C in the presence of an intensifying screen. 
Several precautions were taken to insure that mRNA samples from different patients 
could be compared.  (a)  Ethidium  bromide  was used  to stain each gel before and after 
transfer, confirming that nearly equal amounts of RNA were blotted onto the paper (see 
Fig. 4).  (b) The analysis of individual patients and controls was repeated several times on 
different gels with similar results.  (c) Preliminary studies using mRNA from the controls 
was used to establish the duration of blot exposure which produced a linear relationship 
between mRNA concentration and optical density on x-ray film. (d) These same control 
mRNAs were included on all blots and used as internal controls for determining the level 
of protooncogene expression  by  all  other  RNA  samples.  Hybridization  intensity  was 
calculated  using  a  Hoefer  GS  300  scanning  densitometer  at  a  constant  setting.  The 
hybridization  intensity  of all  samples  was arithmetically  normalized  such  that  identical 
control mRNAs run on different blots gave identical signals when analyzed with the same 
protooncogene probe. The blots were later stripped twice in  100% formamide at 65 °C 
for 1 h, and analyzed with additional probes. 
Purification  and Southern  Blotting  of DNA.  Cell  pellets  were frozen,  lysed with  SDS, 
and  then  treated  with  proteinase  K  (23~ 24).  The  solutions  were  then  extracted  with 
phenol/chloroform, and the supernatants  were exposed to RNase.  After another treat- 
ment with  proteinase  K  and phenol,  DNA was recovered by ethanol precipitation  and 
spooling. Eco RI and Bam HI digests (10 tLg/lane) were electrophoresed on 0.8% agarose 
gels. The size and concentration of oncogene-containing bands were assessed by Southern 
analysis using nick-translated probes. 
Cell Cycle Analysis.  The T  and B cell populations were analyzed by flow cytometry at 
various times after mitogenic stimulation for progress through the cell cycle. DNA content 
of individual cells was measured by staining 2 ×  106 cells with a hypotonic sodium citrate 
solution containing 50 pg/ml propidium iodide and 0. 1%  NP-40 as described previously 
(25). RNA content was measured on 2 ×  106 cells, which had been fixed in 70% ethanol 
and stained with  1% pyronin Y by the method of Shapiro (26). RNA and DNA content 
were also separately measured by staining cells with acridine orange; under the conditions 
used,  RNA emits green fluorescence and DNA red fluorescence (27).  Fluorescence was 
measured  on a  FACS 440  using an argon  ion laser emitting at  488  nm.  The separate 
emissions of acridine orange were determined by using 30 nm band pass dichroic filters 
of 530 nm and below vs. 570 nm and above (28). For each sample, data from 50,000 light 
scatter-gated viable cells were collected. 
Cells were deemed to be in G~ when there was a significant increase in RNA content 
but  not  DNA content,  and  in  G2,  S,  or M  phase  when  a  significant  increase  in  DNA 
content  was  detected  (25-28).  This  was  determined  by  acridine  orange  staining  and 
separately  checked  with  good  agreement  in  all  cases  with  pyronin  Y  for  RNA  and 
propidium iodide for DNA content. Cell volume was also measured to assess the enlarge- 
ment of cells  after  stimulation;  this  was done with  a  Coulter  counter  equipped  with  a 
channelizer as described previously (28). 
OncogeneProbes.  The c-myb probe was a  2.3  kb  Hae  III fragment of a  human  myb 
cDNA  (J.  F.  Mushinski,  unpublished  data).  The  c-myc probe  was  a  5.5  kb  Barn  HI 
fragment from the S107 mouse plasmacytoma line (29). C-abl RNA was detected by a  1.2 
kb Bgl II fragment derived from cloned Ableson murine leukemia virus (30). The N-ras 
probe, a gift from K. Huppi (National Cancer Institute), was a 2 kb Pvu II fragment from KLINMAN ET AL.  1295 
the SK-N-SH neuroblastoma cell line (31). The c-fos probe was a  3 kb Xho I-Nco I 
fragment of the pc-fos (human-l) molecular clone (32), and was a gift from S. Bauer (NCI). 
Results 
Elevated Expression of c-myc in SLE.  Expression of the myc protooncogene by 
PBMC was studied in 17 patients with SLE, 7 normal controls, and in 7 patients 
with  autoimmune diseases  other  than  SLE.  The  top  panel  of Fig.  1  shows 
representative results from this analysis with the myc probe.  Four of the five 
patients with SLE expressed more c-mye RNA than the controls. Elevated c-myc 
expression was also present in the PBMC of the non-SLE autoimmune patients. 
Due to the large number of patients, controls, and standards included in this 
study, no single Northern gel could contain all of the mRNA samples. To permit 
comparison between gels, four control mRNAs were included on each. Protoon- 
cogene expression was measured by optically scanning autoradiographs of the 
blots; the results were then normalized to yield equivalent hybridization intensi- 
ties when identical control mRNAs were run on different blots. Data from all of 
the blots are summarized in Fig.  2.  They show that, on average, PBMC from 
patients  with SLE expressed fourfold more c-myc mRNA than did cells from 
normal volunteers (Fig. 2, first panel). Elevations in c-myc mRNA concentration 
similar in magnitude to those found in SLE were also present in the group of 
patients with nonlupus autoimmune illnesses (Fig. 2, first panel). This is equiva- 
lent to the increase in c-myc mRNA concentration found in human tumors such 
as  Burkitt's  lymphoma and  in  mouse  plasmacytomas,  whose  development is 
associated with abnormal expression of c-myc (33, 34). 
Decreased Expression of c-myb and c-fos in SLE.  Intrigued by the findings with 
c-myc, we examined the expression of two other protooncogenes that encode 
proteins primarily localized to the nucleus: c-myb and c-fos. Elevated levels of c- 
myb  have  been  found  in  tumors of hematopoietic origin  (35,  36),  and  more 
recently in autoimmune lpr/lpr and gld/gld mice (5). 
PBMC  from patients  with  SLE  expressed,  on average,  threefold less  c-myb 
mRNA than  did  normal  controls  (second panel,  Figs.  1  and  2).  This  was  in 
contrast to nonlupus autoimmune patients, whose expression of c-myb was slightly 
elevated when compared to the normal volunteers. 
C-fos encodes a phosphoprotein usually concentrated in the nucleus. Varying 
c-fos expression is associated with different stages of monocyte differentiation in 
both  leukemic and normal individuals (10).  When PBMC  from lupus patients 
were compared to controls, the SLE cells contained considerably lower levels of 
c-fos mRNA (third panel, Figs.  1 and 2).  Interpretation of these data is compli- 
cated  by  the  fact  that  changes  in  c-fos expression  occur  within  minutes  of 
activation (much faster than the other protooncogenes studied). This is less than 
the amount of time required to collect and process the mononuclear cell speci- 
mens and would allow small differences in sample handling to affect results (see 
Discussion).  The seven patients with nonlupus autoimmune diseases showed a 
modest decrease in c-fos expression when compared to normal controls, which 
did not reach the level of statistical significance. 
Expression ofc-abl and N-ras.  C-abl is the cellular homolog of the transforming 
element in Abelson leukemia virus (30, 37). The amount of c-abl mRNA present 1296 KLINMAN  ET AL.  1297 
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FIGURE 2.  The hybridization intensity (with standard error) of various oncogene probes to 
poly(A)  + RNA from  17 lupus patients (n),  7 normal controls (Q), and  3-7 patients with 
nonlupus autoimmune  diseases (m), was determined  by optically scanning Northern blots. 
Means of these values (in arbitrary  units) are presented  graphically. Statistically significant 
differences between patients and controls (p < 0.05) are indicated (*). 
in lupus and other autoimmune PBMC was not significantly different from that 
of normal controls (fourth panel,  Figs.  1 and  2). The average concentration of 
N-ras mRNA,  which encodes a  plasma  membrane protein with  kinase activity 
(38), also did not differ significantly between normal controls and patients with 
SLE (fifth panel, Figs.  1 and 2). However, lupus patients with very active disease 
expressed significantly elevated concentrations of N-ras mRNA when compared 
to normal volunteers (Table I), as did nonlupus patients with active autoimmune 
disease (see below). 
Protooncogene Expression in Active and Inactive Patients.  Of the 17 SLE patients 
studied,  4  had  very active  multisystem  disease  with  accompanying  laboratory 
abnormalities, 8 had mild to moderately active disease, and the remaining 5 were 
in remission. When protooncogene expression in cells from very active patients 
was compared to those from patients with less active disease, elevations in both 
c-myc and N-ras expression were associated with increased disease activity (Table 
II).  These  findings  suggest  that  abnormal  protooncogene  expression  may  be 
associated with the development of disease flares. To rule out the possibility that 
factors other than disease activity might be responsible for the observed differ- 
ences between more active and less active patients, a chart review was conducted. 
Specific organ involvement, type of therapy, and drug dose were not found to 
correlate  significantly  with  protooncogene  expression,  nor  were  there  other 
apparent differences between the patient groups. 
Cellular Oncogenes  in SLE Are Not Rearranged.  Chromosomal translocations 
are frequently associated with the development of malignancies in mice and men 
(39).  This  association  has  been  attributed  (39)  to  the  capacity  of regulatory 
FIGURE  |.  The hybridization pattern of five oncogene probes to mRNA samples from two 
controls, five lupus patients, and two patients with nonlupus autoimmune diseases (rheumatoid 
arthritis and angioimmunoblastic lymphadenopathy) is shown. For each oncogene probe, a 
single gel containing all poly(A)  ÷ RNA samples was run, blotted, and hybridized so that 
conditions would be standard. Numbers above the lanes from the lupus patients correspond 
to the patient profiles presented in Table I. The transcript sizes of  the protooncogene mRNAs 
are shown in kb along the right-hand border. The expression of  actin mRNA, whose expression 
does not vary significantly  during the cell cycle, is shown as a control. 1298  DIFFERENTIAL  ONCOGENE  EXPRESSION 
TABLE  II 
Effect of Disease Activity on Oncogene Expression 
Oncogene 
Group  myc  myb  fos  abl  ras 
Mean  p  Mean  p  Mean  p  Mean  p  Mean  p 
Very active SLE  224  0.03  43  0.02  142  0.001  74  >0.10  272  0.02 
Less activeSLE  77  0.05  36  0.01  74  <0.001  98  >0.I0  89  >0.10 
Normal controls  29  110  646  113  85 
Mean protooncogene expression by patients with very active disease (n -- 4) and less active disease (n 
-- 13) was compared to normal controls (n -- 7). Statistically significant differences, indicated by p 
values <0.05, were determined using the student's t test. 
FIGURE 3.  Southern blot of Barn HI digests of DNA from lupus patients and normal controls 
hybridized with N-ras probe. Gene rearrangement was not found using this or other oncogene 
probes. 
elements  at  the  site  of  translocation  to  abnormally  influence  protooncogene 
expression.  Southern  blots  were  used  to  determine  whether  altered  levels  of 
cellular oncogene expression in patients with SLE were also associated with gene 
rearrangement  or  with  gene  amplification.  DNA  was  isolated  from  PBMC  of 
patients  and  normal  controls  and  then  digested  with  the  Eco  RI  or  Barn  HI 
restriction endonucleases.  Fragments  hybridizing with probes for c-myc, c-myb, c- 
fos,  c-abl, and N-ras were compared  for size and intensity to normal controls on 
the same blot. In no case was there evidence of specific protooncogene  rearrange- 
ment among  the SLE patients, nor was there a  difference in gene dosage. Fig. 3 KLINMAN  ET  AL.  1299 
shows  results  with  N-ras;  the  other  oncogene  probes  similarly  revealed  no 
evidence of gene amplification or rearrangement. 
Protooncogene  Expression in Mitogen-activated Lymphocytes.  To better interpret 
the observed abnormalities of protooncogene expression in patients with autoim- 
mune  diseases,  we  studied  whether cellular  activation  influenced c-onc  gene 
mRNA levels in normal human lymphocytes. PBMC were separated into rela- 
tively pure populations ofT and B cells, which were then stimulated with mitogen 
and cultured for various times in vitro, mRNA isolated from these cells after 0, 
2,  5,  and  18  h  in  culture  was  analyzed for  the  expression  of those  cellular 
oncogenes whose  mRNA  levels  were  significantly different in  the  PBMC  of 
patients vs. normal controls. 
Changes  in  the  concentration  of c-myc  mRNA  have  been  detected  after 
mitogenic stimulation  of mouse spleen  cells (9),  hematopoietic cells (10),  and 
fibroblasts  (40,  41).  In addition,  high  levels of this  oncogene's transcript are 
found in a variety of neoplasms (reviewed in 34). Thus it was not surprising that 
the stimulation of both T  and B lymphocytes induced an elevation in the level 
of c-myc  mRNA (Fig.  4).  From a  very low baseline in  unstimulated cells,  the 
concentration of c-myc RNA rose detectably by 1.5 h after mitogen treatment, 
peaked at 5 h and declined slightly by 18 h. These findings are in keeping with 
previous reports (9, 40, 41) that c-myc expression peaks ~2 h  after stimulation 
and decreases rapidly thereafter. 
c-myb  expression  was  also  analyzed.  High  levels of this  cellular oncogene's 
transcript are associated with hematopoietic tumors including T  cell lymphomas 
and B cell leukemias (35, 36), and with certain autoimmune states (5). Our study 
revealed that increased c-myb expression was induced by the Con A activation of 
purified human T  cells.  The concentration of this protooncogene's transcript 
remained at background levels through 1.5 h in culture then rose to a peak at 5 
h  and persisted  through  18  h  (Fig.  4).  In contrast,  mitogen-activated B  cells 
showed no such rise in c-myb  RNA. This marks an important difference in the 
pattern of c-onc gene expression between activated human T and B lymphocytes. 
It could be argued that LPS is not as strong a mitogen for human B cells as 
Con A is for T  cells. The observed induction of other oncogenes in LPS treated 
B lymphocytes makes such an explanation unlikely. In addition, significant B cell 
proliferation under these conditions was documented both by conventional [3H]- 
thymidine incorporation studies (data not shown) and by analysis of RNA and 
DNA content using cell cycle analysis (see Table III). 
Expression of the c-fos  gene has been linked to differentiation of monocytes 
from leukemic and normal individuals (10),  and has been shown to be a  very 
early event after activation of resting 3T3  fibroblasts (11, 40).  In our studies, 
normal unstimulated PBL showed a  high resting level of c-fos mRNA (Figs.  1 
and 2).  Mitogen activation of either T  or B cells induced a >10-fold decline in 
the concentration of c-fos mRNA within 1.5 h and its reduction to undetectable 
levels at later time points (Fig. 4). 
It is possible but unlikely that changes in c-fos expression were induced by the 
procedures used to purify the lymphocytes. These techniques alone did not lead 
to cellular proliferation or the expression of other protooncogenes (Fig.  1).  In 
addition, high levels of c-fos RNA were found in aliquots of cells isolated at every 1300 KLINMAN ET  AL. 
TABLE  III 
Cell Cycle Analysis of Activated B and T Lymphocytes 
Lymphocytes  Hours post- 
stimulation 
Percent of cells in each stage of cell 
cycle* 
Go  G1  S, G2, M 
B  0  96.4  2.3  1.3 
B  1.5  97.9  1.5  1.6 
B  5  87.5  11.2  1.3 
B  24  82.8  12.0  5.2 
B  48  63.9  11.1  25.0 
T  0  94.6  4.3  1.1 
T  1.5  97.2  1.3  1.5 
T  5  94.8  3.2  2.0 
T  24  86.5  11.2  2.3 
T  48  42.4  16.0  41.6 
* Cells were stained  with acridine orange and tbeir content of RNA and 
DNA was determined by two-color flow cytometry. In comparison to 
resting Go cells, lymphocytes that showed an increase  in RNA but not 
DNA content were defined as being in G~ (11). Cells in S, G2, and M 
were those.expressing  increased levels of DNA. These designations were 
confirmed by independent analysis of RNA and DNA content using 
pyronin Y and propidium iodide, respectively (8, 9). 
1301 
step of the purification procedures, and in an unprocessed human spleen (data 
not shown). Assuming that the short half-life of the c-fos transcript (11, 40) was 
not altered by the collection procedure, these findings argue against the possi- 
bility  that  expression  of this  protooncogene was induced by the purification 
protocol. 
Cell Cycle Analysis  of Activated Lymphocytes.  Mitogen-activated  T  and  B  lym- 
phocytes were stained at various times  with  nucleic acid-binding dyes and then 
analyzed  for  RNA  and  DNA  content  using  a  FACS.  After  48  h  of in  vitro 
culture,  36.1%  of B  cells and 57.6%  of T  cells had been  stimulated  to leave Go 
and enter a  later stage of the cell cycle (Table III). However, after 5 h  in culture 
(when  maximal  changes in protooncogene  expression  were  found), only  12.5% 
of B cells and 5.2% of T  cells had cycled from Go to G~, as defined by a significant 
increase  in  RNA  content  (Table  III and analysis of cell  volume).  Furthermore, 
analysis of DNA  content  showed that very few cells  had progressed  to S  phase 
within  the  first  24  h  of lymphocyte activation  (Table  III).  In  toto,  these  data 
show  that,  while  mitogenic  stimulation  induces a  large  proportion  of T  and  B 
cells  to  progress  through  the  cell  cycle  (consistent  with  results  from  other 
investigators [26, 27]), the characteristic changes in total cellular RNA and DNA 
content that accompany transition  into G1,  S, G~, and  M  lag behind alterations 
in the expression of specific cellular oncogenes. 
FIGURE 4.  Protooncogene expression  by activated  normal T and B lymphocytes.  Lympho- 
cytes were purified from apheresis  samples and then stimulated  with mitogen. Northern blots 
of mRNA isolated from these cells at 0,  1.5, 5, and 18 h poststimulation  were hybridized to 
nick-translated  cellular oncogene probes. The sizes of  major transcripts for each protooncogene 
are shown on the left of each panel. Expression of actin mRNA is shown as a control. 1302  DIFFERENTIAL  ONCOGENE  EXPRESSION 
Discussion 
The concentration of protooncogene mRNA present in PBMC of patients with 
autoimmune diseases was compared to that of normal controls.  The cells from 
patients  with  SLE  had  significantly  more c-myc RNA  than  normal,  and  those 
from  patients  with  active  SLE expressed  significantly  elevated levels of N-ras 
RNA.  Diminished  levels of c-myb and  c-los RNA  were also found  in  the  SLE 
group.  These  findings  were compared  to  cellular  oncogene  levels in  patients 
with nonlupus autoimmune diseases, and to mitogenically activated lymphocytes 
from normal donors. 
While the level of c-myc RNA was highest in patients with active disease, it was 
also significantly elevated in clinically stable patients. We also found that PBMC 
from patients  with  Sjogren's syndrome,  rheumatoid  arthritis,  and  angioimmu- 
noblastic lymphadenopathy expressed elevated c-myc RNA. Purposeful stimula- 
tion of normal  PBMC resulted in an increase in c-myc mRNA concentration  in 
both T  and B cell populations. These findings suggest that lymphocyte activation, 
induced  by mitogen  in  vitro  or  by autoimmune  disease  in  vivo,  leads  to  an 
increase in c-myc expression. These data are consistent with the increased prolif- 
eration  of B  cells reported  (42) in  patients  with stable SLE, even  though  they 
may not have increased numbers of immunoglobulin-secreting cells (43, 44). 
N-ras mRNA was not found to be significantly elevated in the SLE group as a 
whole, but was increased in patients with active disease. A similar result has been 
reported in mice with lupus-like disorders. The B cells of NZB and BXSB mice 
had elevated N-ras and c-myc expression. When congenic NZB.xid and BXSB.xid 
mice were bred and tested (the xid gene markedly retarding  B cell maturation 
and the production of autoantibodies [45]) expression of these protooncogenes 
was subnormal (5). 
In contrast  to the elevation in c-myc and N-ras, c-rayb and c-los mRNA levels 
were significantly decreased in patients with both active and inactive SLE. Since 
c-fos expression falls rapidly following lymphocyte activation (Fig. 5), these data 
suggest that some degree of PBMC stimulation is present in these patients. 
An explanation  for low c-myb expression presents itself in the data on mitogen 
stimulated lymphocytes. High c-myb RNA appeared to be a feature of stimulated 
T  cells, but not B cells (Fig. 4, second panel). Therefore, if an individual's disease 
were characterized by the specific activation of B cells, one might anticipate low 
c-myb and high c-myc RNA levels. This pattern is found in patients with SLE but 
not in those with other autoimmune diseases (where decreased expression of c- 
myb was not found). Whether this observation will be of use in diagnosing patients 
with clinically undifferentiated rheumatic disease will require further study. 
Our results also show that mitogenic activation of human lymphocytes induces 
an  orderly  sequence  of change  in  the  level  of expression  of specific  cellular 
oncogenes (Fig.  5).  Shortly after activation,  the concentration  of c-fos message 
declines.  At  ~1.5  h,  an  increase in  the expression  of c-myc occurs, reaching  a 
maximum at 5 h and persisting for at least 18 h. Also at 5 h, an increase in c-myb 
expression is detected in the T  cell pool but not among B cells. These changes 
precede the rise in total cellular RNA content associated with transition  from a 
resting Go to an activated G~ state. 
Cell  cycle  analysis  of  the  T  and  B  cell  populations  showed  that  a  large KLINMAN  ET  AL.  1303 
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FtGUR~  5.  Protooncogene expression in activated normal T  and B lymphocytes over time. 
Autoradiographs of the northern blots presented in  Fig.  4,  whose hybridization intensities 
were within the linear response range of the Hoefer GS 300, were selected for further ana)ysis. 
The radiographs were optically scanned at the level of each protooncogene, and hybridization 
intensity was used to determine protooncogene expression, which was plotted as a function of 
time. 
proportion of cells in both populations responded to mitogenic stimulation within 
48 h. At 1.5 h, however, there was no significant increase in RNA content among 
the activated lymphocyte populations, and only 5% of T  cells and 12% of B cells 
had entered G] by 5 h (26, 27). None reached S phase by this time. These data 
suggest that protooncogene expression changes before a cell's transition through 
the  cell  cycle.  This  is  especially clear  in  the  case  of c-los, whose  expression 
decreased fivefold within 1.5 h of stimulation. While it might be argued that the 
elevated expression of other protooncogenes was moderated by the small number 
of cells leaving G] by 5 h, this seems unlikely, since the number of cells leaving 
Go remained high for over 24 h, yet the levels of myb and abl RNA fell to near 
resting levels by 18 h. 
The sequential activation of c-fos, c-myc, and then c-myb (Fig.  5) supports the 
contention that such cellular oncogenes perform vital cellular functions and are 
specifically involved in growth and differentiation (9).  Further, it is consistent 
with the concept of a cascade whereby altered expression of one protooncogene 
is  required  before changes in  the expression  of another protooncogene may 
occur (9, 40). All cellular oncogenes are not involved in this cascade, however. 
The stimulation of T  and B lymphocytes led to no change in the level of N-ras 
mRNA in our study (data not shown). Our finding that c-myb expression increased 
in activated T  cells but not in activated B cells demonstrates that, even among 
closely related tissue types, cellular activation involves precise and independent 
regulation of the expression of specific cellular oncogenes. This understanding 
of protooncogene expression by normal lymphocytes has cleared the way for the 
interpretation of abnormal cellular oncogene expression in autoimmune disease 
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These studies are an attempt to determine whether specific genes are differ- 
entially expressed in patients with autoimmune disease (5). Our results indicate 
that  abnormalities  in  protooncogene  mRNA  levels  are  frequently  found  in 
patients with SLE. Whether these abnormalities stem from intrinsic defects in 
gene  regulation,  increased  lymphocyte activation,  or  expansion  of particular 
lymphocyte subpopulations in diseased individuals has not yet been determined. 
These alternatives are not mutually exclusive. We believe that future studies of 
differential gene expression will better define the molecular bases ofautoimmune 
diseases. Such studies may include the isolation of genes associated with autoim- 
munity, followed by the characterization of their protein products and analysis 
of the mechanism(s) by which such products lead to abnormal cellular activation 
and differentiation. 
Summary 
PBMC  from patients  with autoimmune diseases  and  from  normal  controls 
were studied for the expression of several cellular oncogenes. Gene expression 
was assessed by Northern blot analysis of poly(A)  + RNA obtained from leuka- 
pheresis samples. Patients with SLE expressed significantly more c-myc protoon- 
cogene  RNA  than  did  normal  controls.  Increased  expression  of  the  N-ras 
protooncogene was found in that subset of patients whose autoimmune disease 
was very active. Cells from individuals with SLE, but not from those with other 
autoimmune illnesses, showed significantly decreased levels of the c-myb and c- 
fos protooncogenes. 
To examine the implications of these findings, B and T  cells  were purified 
from apheresis samples donated by normal volunteers. When mitogen was used 
to activate the B cells in vitro, their pattern ofprotooncogene expression changed 
to resemble that found in freshly isolated cells from lupus patients. These results 
suggest that  the differences detected in  the expression  of protooncogenes by 
patients with SLE may be due to the abnormal activation of their B cells in vivo. 
The pattern of protooncogene expression found in patients with other autoim- 
mune illnesses is consistent with the activation of additional cell types in those 
diseases. 
We thank Jeffrey Siegel for his helpful review and criticism of this work, and Steve Bauer 
and Konrad Huppi for their preparation of probes and for their advice. 
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